Vaxart Achieves Q1 Profitability, Extends Cash Runway, and Secures New $25M Financing

summarizeSummary

Vaxart reported a significant financial turnaround in Q1 2026, achieving net income of $5.2 million and extending its cash runway into Q2 2027, further bolstered by a new $25 million share purchase agreement.

check_boxKey Events

• Achieved Q1 Profitability

  Vaxart reported net income of $5.2 million for Q1 2026, a significant improvement from a $15.6 million net loss in Q1 2025.

• Extended Cash Runway

  Cash, cash equivalents, and investments totaled $61.0 million as of March 31, 2026, providing an anticipated cash runway into the second quarter of 2027.

• Secured New $25M Financing Facility

  The company entered a share purchase agreement with Lincoln Park Capital Fund, LLC on April 16, 2026, providing the right to sell up to $25 million of common stock over 24 months, offering flexible access to capital.

• COVID-19 Trial Update

  Topline 12-month safety and immunogenicity data from the 400-person sentinel cohort of the Phase 2b COVID-19 trial is anticipated in Q2 2026, with primary data from the larger 5,000-participant cohort expected in early 2027.

auto_awesomeAnalysis

This 8-K, accompanying the Q1 2026 financial results, signals a critical positive shift for Vaxart. The company's return to profitability and the extension of its cash runway into the second quarter of 2027 directly address and alleviate the previously disclosed going concern warning. The new $25 million share purchase agreement with Lincoln Park Capital Fund provides additional financial flexibility, complementing the existing $49.7 million ATM program. These developments significantly improve the company's financial stability and outlook, supporting ongoing clinical milestones for its COVID-19 and norovirus vaccine programs.